Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial
复制标题
DOI：
10.1136/ard.2009.117036
复制
发表时间：
2010-06-01
影响因子：
27.4
通讯作者：
Derksen, R. H. W. M.
中科院分区：
文献类型：
--
作者：
Hartkamp, A.;Geenen, R.;Derksen, R. H. W. M.
目的脱氢表雄酮（DHEA）可改善疲劳和健康状况。这两种疾病都是系统性红斑狼疮（SLE）患者的主要问题，即使是静止期疾病。低血清DHEA水平在SLE中是常见的。目前的工作调查的影响DHEA管理的疲劳，幸福和功能的妇女与非活动性SLE.Methods在一项双盲，随机，安慰剂对照研究，60名女性患者与非活动性SLE接受200毫克口服DHEA或安慰剂。主要结果指标为全身疲劳、抑郁情绪、心理健康和身体功能。分别在治疗前、用药3、6、12个月后和停药6个月后进行评估。结果DHEA组和安慰剂组患者的全身疲劳（p < 0.001）和心理健康（p = 0.04）均有改善。DHEA无差异效应。相信DHEA已被使用是一个更强的预测改善一般疲劳比实际使用的DHEA（p = 0.04）。结论该试验并没有表明每天200毫克口服DHEA对疲劳和幸福的影响，因此DHEA治疗不建议在女性患者静止SLE。
Objective Dehydroepiandrosterone (DHEA) has been reported to improve fatigue and reduced well-being. Both are major problems in patients with systemic lupus erythematosus (SLE), even with quiescent disease. Low serum DHEA levels are common in SLE. The present work investigates the effects of DHEA administration on fatigue, well-being and functioning in women with inactive SLE.Methods In a double-blind, randomised, placebo-controlled study, 60 female patients with inactive SLE received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being and physical functioning. Assessments were made before treatment, after 3, 6 and 12 months on medication, and 6 months after cessation of treatment.Results Patients from the DHEA and placebo group improved on general fatigue (p < 0.001) and mental wellbeing (p = 0.04). There was no differential effect of DHEA. The belief that DHEA had been used was a stronger predictor for improvement of general fatigue than the actual use of DHEA (p = 0.04).Conclusions The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.